Hitachi Construction Machinery Co Ltd (HCM)
XHAN 
Summary
HCM Chart
Braveheart Bio: In Non-Obstructive HCM, The Therapeutic Window Is The Product
Braveheart Bio is undervalued as a late-stage HCM player, with two Phase 3 programs fully funded and a differentiated molecule for non-obstructive HCM. BRVE holds $527M in pro forma cash, supporting operations into 2029 and enabling completion of LIONHEART-HCM and NOBLEHEART-HCM trials. Phase 2 data show rapid, reversible effects with minimal LVEF decline, supporting a favorable safety profile and clinical flexibility versus competitors.
Lexicon Pharmaceuticals: Upgrading On Sotagliflozin HCM Data In Q1 '27 And More
Lexicon Pharmaceuticals, Inc. upgraded to Buy as multiple near-term catalysts emerge across its pipeline. LXRX anticipates NDA resubmission for ZYNQUISTA in T1D by Q4 2026, contingent on STENO1 safety data. Top-line results from the pivotal phase 3 SONATA-HCM trial for sotagliflozin in HCM are expected in Q1 2027.
Lexicon Completes SONATA-HCM Enrollment, Eyes 2027 Sotagliflozin Data
Lexicon Pharmaceuticals NASDAQ: LXRX said it has completed enrollment in its Phase III SONATA-HCM study of sotagliflozin in hypertrophic cardiomyopathy, with topline data expected in the first quarter of 2027.
Hitachi Construction Machinery Co Ltd (HCM) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Hitachi Construction Machinery Co Ltd ever had a stock split?
Hitachi Construction Machinery Co Ltd Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Chig Fung Cheng CEO | XHAN Exchange | US44842L1035 ISIN |
| HK Country | 1,796 Employees | - Last Dividend | 30 May 2019 Last Split | - IPO Date |
Overview
HUTCHMED (China) Limited specializes in discovering, developing, and commercializing innovative treatments for cancer and immunological diseases, operating on a global scale with a significant presence in Hong Kong. Initially founded in 2000 as Hutchison China MediTech Limited, the company underwent a rebranding to HUTCHMED (China) Limited in May 2021, underscoring its evolution and growing ambitions in the healthcare sector. With its headquarters based in Central, Hong Kong, HUTCHMED has forged strategic collaborations with industry giants such as AstraZeneca, Lilly (Shanghai) Management Company, BeiGene, Innovent Biologics, and several others, facilitating the advancement of its robust pipeline geared towards addressing unmet medical needs in oncological and immunological disorders. Leveraging cutting-edge research and development capabilities, HUTCHMED aims to lead in the creation of targeted therapeutics and immunotherapies, positioning itself as a key player in the fight against some of the most challenging diseases.
Products and Services
- Savolitinib: An innovatively designed inhibitor targeting MET gene mutations, Savolitinib offers a new hope in the treatment of non-small cell lung cancer (NSCLC), various renal cancers, colorectal cancer (CRC), and gastric cancer (GC), providing patients with an option that specifically tackles the genetic basis of their condition.
- Fruquintinib: This highly selective inhibitor focuses on vascular endothelial growth factor receptors (VEGFR), crucial in tumor-induced angiogenesis. It's formulated for the management of CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, alongside various gastrointestinal and solid tumors, presenting a versatile option in anti-cancer care.
- Surufatinib: Targeting a broad spectrum of neuroendocrine tumors (NET), Surufatinib offers therapeutic possibilities for both pancreatic and non-pancreatic NET, biliary tract cancer, sarcoma, among others, by inhibiting angiogenesis and immune evasion pathways.
- Tazemetostat: An EZH2 inhibitor, Tazemetostat is employed in treating specific cases of epithelioid sarcoma and follicular lymphoma, exploiting epigenetic mechanisms to halt tumor growth.
- HMPL-523, HMPL-689, and Other Inhibitors: A diverse range of inhibitors like HMPL-523, targeting spleen tyrosine kinase, and HMPL-689, focusing on phosphoinositide 3'-kinase delta (PI3Kδ), among others, underscore HUTCHMED’s dedication to addressing various hematological cancers and chronic immune diseases with precision medicine.
- Collaborative Projects: In addition to its in-house developed therapies, HUTCHMED’s strategic alliances with pharmaceutical and biotech companies have enabled the development and commercialization of next-generation therapeutics, enhancing its portfolio and therapeutic impact.
Contact Information
